Sorafenib prolongs survival in patients with advanced RCC
This article has no abstract so we have provided the first paragraph of the full text.
Systemic therapies for patients with renal cell carcinoma (RCC) include high-dose interleukin 2 and interferon 
; however, these cytokines rarely induce complete response or prolonged survival and are not always well tolerated. Sorafenib, a multiprotein kinase inhibitor, has been shown to have antitumor activity in renal adenocarcinoma animal models and to prolong survival in patients with metastatic RCC. In a phase III trial, Escudier et al. showed that sorafenib prolonged survival in patients with advanced clear-cell RCC in whom previous therapy had failed.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.